andersen ondansetron use in early pregnancy and the risk of congenital malformations
Congenital heart defects. Cleft palate. Kidney malformation.Andersen, JT, et al, Ondansetron use in early pregnancy and the risk of congenital malformations, Department of Pharmacology, Bispebjerg Hospital, Accessed on 11 February 2015 http  B. Danielsson, B.N. Wikner, B. Klln, Use of ondansetron during pregnancy and congenital malformations in the infant, Reprod.Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects, Birth Defects Res. A Clin. Mol. 1. To appreciate the role of genetics and the environment (teratogenic exposure) in congenital malformations.1.5/2.5). At about age 35, the risk of having a trisomic infant increases to about 1, roughly equivalent to the risk in the early days of amniocentesis of a pregnancy loss as a There is evidence that certain antiepileptic drugs (AEDs) are teratogenic and are associated with an increased risk of congenital malformation. The majority of women with epilepsy continue taking AEDs throughout pregnancy The risk of neonatal congenital malformations in mothers exposed to MMI/CMZ PTU was significant higher than that in the No ATD groups (OR 1.76 9518. Andersen SL, Olsen J, Wu CS, Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study.
Only limited data concerning the safety of ondansetron in pregnancy is available. Therefore we conducted a nationwide cohort study testing the hypothesis use of ondansetron during the first trimester was associated with a higher prevalence of congenital malformations. "Ondansetron in pregnancy and risk of adverse fetal outcomes"."Use of ondansetron during pregnancy and congenital malformations in the infant". Abstract OBJECTIVE To quantify the risk of major congenital malformations (MCMs) associated with gestational combination antiretroviral use. DESIGN Population-based prospective cohort study. METHODS Using the Quebec Pregnancy Cohort from 1998 to 2015 wk use during pregnancy and survival (adjusted OR 0.7, 95 condence 6). The rate of congenital anomalies was not increased after applica- interval (CI) 0.41.1) or congenital malformation rates (adjusted OR tion of sertraline in early pregnancy (9/161 5.
6 vs 25/633 3.9 0.9, 95 CI To date, seven observational studies including data from a total of approximately 2500 women who used oseltamivir during pregnancy found no increased risks of congenital malformations or other adverse pregnancy Of major concern, Andersens study detected a 2-fold increased risk of cardiac malformations with ondansetron odds ratio 2.0 (95 confidence interval [CI], 1.33.1)Ondansetron Use in Early Pregnancy and the Risk of Congenital Malformations—A Register Based Nationwide Control Study. Ondansetron Use In Early Pregnancy And The Risk Of Congenital. Recently a Danish study found no increased risk of major malformations overall in women. Birth defects after exposure to misoprostol in the first trimester of. Ondansetron Use in Early Pregnancy and the Risk of Congenital Malformations— A Register Based Nationwide Control Study. International Society of Pharmaco-epidemiology. Montreal, Canada 2013. Earlier studies re-ported that nearly 10 of infants with lethal mul-tiple congenital malformations have abnormal cytogenetic studies.23Environmental factors such as cigarette smoking appear to play a role in the occurrence of these malformations.5 Alcohol use in pregnancy increases the risk Ondansetron use in early pregnancy and the risk of congenital malformations - a register based nationwide cohort study. Jon T. Andersen et al. International Society of Pharmaco-epidemiology. 4.7 of women who were prescribed Ondansetron (Zofran) had a child born with some type of congenital malformation. Zofran use during the first trimester of pregnancy doubled the risk of a child being born with a congenital heart defect. Andersen, JT et al. (2013). Ondansetron Use in Early Pregnancy and the Risk of Congenital Malformations—A Register Based Nationwide Control Study. International Society of Pharmaco-epidemiology. Andersen, et al Ondansetron Use in Early Pregnancy and Risk of Congenital Malformations A Register-Based Nationwide Control Study, presented at the International Society of Pharmaco-epidemiology, Montreal, Canada (2013) Logistic regression models were used to estimate the associations between fever in first trimester and overall congenital malformations and congenitalConclusions: Overall, this study did not show any association between maternal fever in pregnancy and risk of congenital anomalies." Table 3. List of congenital malformations after exposure to montelukast in early pregnancy.Table 4. Odds ratio (OR) or Risk Ratio (RR) for congenital malformations after maternal use of montelukast or other long-acting anti-asthmatic drugs, adjusted for year of birth, maternal age, parity, smoking and Data from the Swedish Medical Birth Register combined with the Swedish Register of Prescribed Drugs were used to identify 1349 infants born of women who had taken ondansetron in early pregnancy, 1998-2012. Presence of congenital malformations in the offspring was identified with three national Ondansetron Use in Early Pregnancy Dr. Jon T. Andersen, Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark View presentation.Baseline risk.Causes of congenital malformations. — Study: Ondansetron use in early pregnancy and the risk of congenital malformations—a register based nationwide cohort study, Andersen et al. In a second Danish study in 2013, researchers expand their data to include 897,018 births. Response: Our findings suggest that use of antipsychotics early in pregnancy does not meaningfully increase the risk for congenital malformations overall or cardiac malformations, with the possible exception of risperidone. Also, stratified analyses of the association between various measures of fever in first trimester and overall congenital malformations according to antipyretic use in the first trimester were performed.Maternal fever during early pregnancy and the risk of oral clefts. Birt Defects Res A Clin Mol Teratol. The aim of the study was to investigate whether clarithromycin use in early pregnancy was associated with an increased risk for miscarriages and major malformations.The primary outcome was the number of miscarriages and offspring with major congenital malformations among users of Pasternak B, Svanstrm H, Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes.First-trimester drug use and congenital disorders. Obstet Gynecol 198565(4):45155.Constipation and headaches. Ondansetron: B1 no increased risk of major fetal malformations Presence of congenital malformations in the offspring was identified with three national health registers. In a Mantel-Haenszel analysis adjustment was made for year of delivery, maternal age, parity, smoking in early pregnancy and pre-pregnancy body mass index. Risks were expressed as odds In addition, estimates were adjusted for hospitalization for nausea and vomiting during pregnancy (as a proxy for severity) and the use of other antiemetics.Documents. Ondansetron: no increase in risk of fetal malformations. Highlights This register based study investigated malformations after use in early pregnancy. An increased risk for cardiovascular defects, notably septum defects, was observed.Presence of congenital malformations in the offspring was identified with three national health Pharmaceuticals 6:12211285 Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Nrgaard M (2010) Use of selective serotonin-uptake inhibitors during early pregnancy and risk of congenital malformations: Update analysis. Conclusions: We recommend avoiding use of ondansetron in early pregnancy and discussing the potential increased risk of congenital malformations with pregnant patients before its use. Level B recommendation. Ondansetron use in early pregnancy and the risk of congenital malformations a registry based nationwide cohort study. Montreal, Canada: International Society of Pharmaco-Epidemiology 2013.